For research use only. Not for therapeutic Use.
Cergutuzumab amunaleukin（Cat No.:I042142）is an investigational antibody-drug conjugate (ADC) that targets HER2 (human epidermal growth factor receptor 2), a protein overexpressed in various cancers, including breast and gastric cancer. The antibody component, cergutuzumab, binds specifically to HER2 on tumor cells, while the amunaleukin component is a modified interleukin-2 (IL-2) that helps stimulate the immune system. This combination is designed to selectively deliver a potent immune-enhancing agent to cancer cells, improving immune response and potentially enhancing tumor destruction. It is being studied in clinical trials for its efficacy in HER2-positive cancers.
| Catalog Number | I042142 |
| CAS Number | 1509916-03-3 |
| Purity | ≥95% |
